Kuvatris Therapeutics, Inc.
DelistedCIK 1811623fmd_024PHPNB1K0DJSXFSYG8VZHM5VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2024, 14 periods
| Line item | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Total revenues | – | 0 | 0 |
| Research and development | 2 | 2 | 4 |
| Total operating expenses | 7 | 11 | 16 |
| Operating income | (7) | (11) | (16) |
| Interest expense | 3 | 0 | 0 |
| Other non-operating income (expense) | (3) | (4) | (2) |
| Income before taxes | – | (15) | (18) |
| Income tax expense | – | 0 | 0 |
| Net income from continuing operations | – | (15) | (18) |
| Net income | (10) | (15) | (18) |